CA3180559A1 - Administration of cebp-beta antagonist and methods of use - Google Patents
Administration of cebp-beta antagonist and methods of use Download PDFInfo
- Publication number
- CA3180559A1 CA3180559A1 CA3180559A CA3180559A CA3180559A1 CA 3180559 A1 CA3180559 A1 CA 3180559A1 CA 3180559 A CA3180559 A CA 3180559A CA 3180559 A CA3180559 A CA 3180559A CA 3180559 A1 CA3180559 A1 CA 3180559A1
- Authority
- CA
- Canada
- Prior art keywords
- patient
- pharmaceutical composition
- administered
- administration
- infusion
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Reproductive Health (AREA)
- Oncology (AREA)
- Marine Sciences & Fisheries (AREA)
- Endocrinology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (13)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063041990P | 2020-06-21 | 2020-06-21 | |
| US202063041989P | 2020-06-21 | 2020-06-21 | |
| US202063041986P | 2020-06-21 | 2020-06-21 | |
| US202063041988P | 2020-06-21 | 2020-06-21 | |
| US202063041991P | 2020-06-21 | 2020-06-21 | |
| US63/041,988 | 2020-06-21 | ||
| US63/041,991 | 2020-06-21 | ||
| US63/041,986 | 2020-06-21 | ||
| US63/041,989 | 2020-06-21 | ||
| US63/041,990 | 2020-06-21 | ||
| US202163172560P | 2021-04-08 | 2021-04-08 | |
| US63/172,560 | 2021-04-08 | ||
| PCT/US2021/038264 WO2021262604A2 (en) | 2020-06-21 | 2021-06-21 | Administration of cebp-beta antagonist and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3180559A1 true CA3180559A1 (en) | 2021-12-30 |
Family
ID=79281738
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3180559A Pending CA3180559A1 (en) | 2020-06-21 | 2021-06-21 | Administration of cebp-beta antagonist and methods of use |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20230218717A1 (https=) |
| EP (1) | EP4168033B1 (https=) |
| JP (1) | JP2023531683A (https=) |
| KR (1) | KR20230027054A (https=) |
| CN (1) | CN115768458A (https=) |
| AU (1) | AU2021297172B2 (https=) |
| BR (1) | BR112022025880A2 (https=) |
| CA (1) | CA3180559A1 (https=) |
| FI (1) | FI4168033T3 (https=) |
| IL (1) | IL299104A (https=) |
| MX (1) | MX2022016478A (https=) |
| NZ (1) | NZ795026A (https=) |
| PT (1) | PT4168033T (https=) |
| WO (1) | WO2021262604A2 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2025532391A (ja) * | 2022-10-07 | 2025-09-29 | サピエンス・セラピューティクス・インコーポレーテッド | Ｃ／ｅｂｐ－ベータアンタゴニスト及び免疫調節剤の使用 |
| WO2024216238A2 (en) * | 2023-04-13 | 2024-10-17 | Sapience Therapeutics, Inc. | Use of beta-catenin antagonist and immunomodulator |
| AU2024252321A1 (en) * | 2023-04-13 | 2025-10-16 | Sapience Therapeutics, Inc. | Administration of a beta-catenin antagonist and methods of use |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2016516669A (ja) * | 2013-02-22 | 2016-06-09 | ザ トラスティーズ オブ コロンビア ユニバーシティ イン ザ シティ オブ ニューヨーク | 転写因子ａｔｆ５の阻害により腫瘍細胞を阻害するための組成物および方法 |
| US10899834B2 (en) * | 2015-04-16 | 2021-01-26 | H. Lundbeck A/S | Anti-PACAP antibodies |
| WO2018152446A2 (en) * | 2017-02-20 | 2018-08-23 | Sapience Therapeutics, Inc. | Cell-penetrating atf5 polypeptides and uses thereof |
| WO2019136125A1 (en) * | 2018-01-03 | 2019-07-11 | Sapience Therapeutics, Inc. | Atf5 peptide variants and uses thereof |
| WO2020033555A2 (en) * | 2018-08-08 | 2020-02-13 | The Trustees Of Columbia University In The City Of New York | Dominant negative cebpb and cebpd proteins and methods of use for decreasing viability of neoplastic cells |
-
2021
- 2021-06-21 PT PT218289023T patent/PT4168033T/pt unknown
- 2021-06-21 KR KR1020227044587A patent/KR20230027054A/ko active Pending
- 2021-06-21 WO PCT/US2021/038264 patent/WO2021262604A2/en not_active Ceased
- 2021-06-21 JP JP2022579019A patent/JP2023531683A/ja active Pending
- 2021-06-21 NZ NZ795026A patent/NZ795026A/en unknown
- 2021-06-21 CA CA3180559A patent/CA3180559A1/en active Pending
- 2021-06-21 BR BR112022025880A patent/BR112022025880A2/pt unknown
- 2021-06-21 CN CN202180044276.8A patent/CN115768458A/zh active Pending
- 2021-06-21 MX MX2022016478A patent/MX2022016478A/es unknown
- 2021-06-21 US US18/011,171 patent/US20230218717A1/en active Pending
- 2021-06-21 EP EP21828902.3A patent/EP4168033B1/en active Active
- 2021-06-21 FI FIEP21828902.3T patent/FI4168033T3/fi active
- 2021-06-21 IL IL299104A patent/IL299104A/en unknown
- 2021-06-21 AU AU2021297172A patent/AU2021297172B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021262604A3 (en) | 2022-02-17 |
| CN115768458A (zh) | 2023-03-07 |
| KR20230027054A (ko) | 2023-02-27 |
| FI4168033T3 (fi) | 2026-04-07 |
| JP2023531683A (ja) | 2023-07-25 |
| BR112022025880A2 (pt) | 2023-01-10 |
| EP4168033B1 (en) | 2026-02-25 |
| US20230218717A1 (en) | 2023-07-13 |
| EP4168033A2 (en) | 2023-04-26 |
| AU2021297172A1 (en) | 2023-01-19 |
| AU2021297172B2 (en) | 2025-01-30 |
| EP4168033A4 (en) | 2024-06-19 |
| IL299104A (en) | 2023-02-01 |
| NZ795026A (en) | 2026-03-27 |
| PT4168033T (pt) | 2026-03-24 |
| MX2022016478A (es) | 2023-02-01 |
| WO2021262604A2 (en) | 2021-12-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2759129C (en) | Treatment of ovarian cancer using an anticancer agent conjugated to an angiopep-2 analog | |
| AU2021297172B2 (en) | Administration of CEBPβ antagonist and methods of use | |
| US12528846B2 (en) | BH4 stabilized peptides and uses thereof | |
| CN111263635A (zh) | Nr4a1配体、药物组合物以及相关使用方法 | |
| JP2023531683A5 (https=) | ||
| IL323919A (en) | Administration of a beta-catenin antagonist and methods of use | |
| US20240358701A1 (en) | Pharmaceutical compositions and combinations comprising inhibitors of the androgen receptor and uses thereof | |
| WO2024006207A1 (en) | An n-terminal domain androgen receptor inhibitor and uses thereof | |
| US20230165933A1 (en) | Peptides containing a pcna interacting motif for use in the treatment of solid cancer | |
| WO2024077297A2 (en) | Use of c/ebp-beta antagonist and immunomodulator | |
| AU2017248264A1 (en) | Compositions and methods for treating pancreatitis and pain with death receptor agonists | |
| WO2024216238A2 (en) | Use of beta-catenin antagonist and immunomodulator | |
| WO2025110250A1 (ja) | 改変ｍｆｇ－ｅ８タンパク質 | |
| HK40022745A (en) | Nr4a1 ligands, pharmaceutical compositions, and related methods of use | |
| EA041148B1 (ru) | Композиции и способы для лечения панкреатита и боли с применением агонистов рецептора смерти | |
| HK1167347B (en) | Treatment of ovarian cancer using an anticancer agent conjugated to an angiopep-2 analog |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250520 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250520 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20250618 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20250618 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250618 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250826 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20250826 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250826 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250826 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250827 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D120 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: VOLUNTARY SUBMISSION OF PRIOR ART RECEIVED Effective date: 20251027 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D123 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIOR ART DISCLOSURE DETERMINED COMPLIANT Effective date: 20260303 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260303 Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260303 |